TY  - BOOK
AU  - Burman, Kenneth D
AU  - Kulkarni, Kanchan
AU  - Moreau, Shari
AU  - Van Nostrand, Douglas
AU  - Wartofsky, Leonard
AU  - Wu, Di
TI  - Poor patient compliance with instructions for continuous sialogogues after <sup>131</sup> I therapy
SN  - 1354-523X
PY  - 2019///
KW  - *Medication Adherence
KW  - *Salivation/de [Drug Effects]
KW  - *Sialadenitis/dt [Drug Therapy]
KW  - *Thyroid Neoplasms/rt [Radiotherapy]
KW  - *Xerostomia/dt [Drug Therapy]
KW  - Adult
KW  - Aged
KW  - Female
KW  - Humans
KW  - Iodine Radioisotopes/tu [Therapeutic Use]
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Sialadenitis/et [Etiology]
KW  - Surveys and Questionnaires
KW  - Thyroid Neoplasms/co [Complications]
KW  - Xerostomia/et [Etiology]
KW  - MedStar Washington Hospital Center
KW  - Medicine/Endocrinology
KW  - Medicine/Nuclear Medicine
KW  - Journal Article
N2  - CONCLUSION: Despite repetitive instructions to use sialogogues continuously, most patients (90%) were not compliant. In future studies, strict monitoring and evaluation of patient compliance will be crucial when assessing the effect of continuous versus intermittent or delayed initiation of sialogogues; Copyright (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved; METHODS: Differentiated thyroid cancer patients who were clinically scheduled for an <sup>131</sup> I therapy at MedStar Washington Hospital Center between 2012 and 2013 were given instructions for continuous sialogogues per standard clinical protocol. The prospective survey was given at multiple time points; OBJECTIVES: To analyze the role of patient compliance as a factor in evaluating the effectiveness of continuous sialogogues to prevent salivary side effects from <sup>131</sup> I therapy in differentiated thyroid cancer patients; RESULTS: Ninety-nine patients consented to participate of whom 94 participants had complete data. The mean prescribed <sup>131</sup> I activity was 121 +/- 50 mCi (4.5 +/- 1.9 GBq), range 27.5-288 mCi (1.0-10.7 GBq ). Overall, only 10% (9/94) of patients were compliant with continuous sialogogues. Even though all patients took sialogogues on the first day of post-therapy, 17% of participants did not continuously take sialogogues during the first day, 60% during the first night, and 72% on the second day despite rigorous instructions to continue for two days
UR  - https://dx.doi.org/10.1111/odi.12969
ER  -